The Healthtech Podcast #400 Neil Daly from Skin Analytics: How can we use AI to diagnose skin cancer?
6 snips
May 14, 2025 Neil Daly, Founder and CEO of Skin Analytics, discusses the revolutionary role of AI in skin cancer diagnosis. He shares insights on the development of their medical device, DERM, which has gained regulatory approval in the UK. The conversation highlights how AI technology can enhance early diagnosis and improve patient outcomes, while emphasizing the importance of human oversight and patient trust. Daly also navigates the challenges of compliance and funding within the healthcare landscape, painting an optimistic picture for the future of AI in medicine.
AI Snips
Chapters
Transcript
Episode notes
Understanding Class III Device Importance
- Class three medical devices involve the highest level of regulatory oversight due to patient risk.
- Skin Analytics' AI is class three because incorrect decisions could delay cancer diagnosis, risking patient harm.
Clarifying Autonomous AI Use
- Autonomous AI acts independently to triage skin lesions within a clinical pathway.
- It evaluates images and can discharge benign cases, integrating safety nets and clinician oversight.
Large Scale AI Clinical Use
- Over 160,000 patients have had AI skin lesion evaluations since 2020, with 70,000 last year alone.
- This volume provides robust real-world data to monitor AI performance and safety.